Clinical trial • Phase IV • Psychiatry
CANNABIDIOL for Post-traumatic stress disorder | Anxiety disorders
Phase IV trial of CANNABIDIOL for Post-traumatic stress disorder | Anxiety disorders. Placebo (Softisan 378); dose/schedule not specified-controlled.
Overview
- Trial Therapeutic Area
- Psychiatry
- Trial Disease
- Post-traumatic stress disorder | Anxiety disorders
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule | Other
Key dates
- Initial CTIS Submission Date
- 07-10-2024
- First CTIS Authorization Date
- 29-10-2024
Trial design
Placebo (Softisan 378); dose/schedule not specified-controlled Phase IV trial in Netherlands.
- Comparator
- Placebo (Softisan 378); dose/schedule not specified
- Target Sample Size
- 82
- Trial Duration For Participant
- 14
Eligibility
Recruits 82 No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants are adults (Age between 18-65). Specific consent/assent handling details not specified in the provided data..
- Pregnancy Exclusion
- For women: pregnant, a wish to become pregnant, or nursing
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants are adults (Age between 18-65). Specific consent/assent handling details not specified in the provided data.
Inclusion criteria
- {"criterion_text":"- Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans.\n- Age between 18-65\n- Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)"}
Exclusion criteria
- {"criterion_text":"- Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)\n- Alcohol and/or drug dependence\n- Inability to adequately read or speak Dutch\n- (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities\n- (a history of) allergies to medication (adverse reactions or rash)\n- Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)\n- Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening.\n- Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD\n- For women: pregnant, a wish to become pregnant, or nursing"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Beck’s anxiety index between the first and second week.","definition_or_measurement_approach":"Not specified in the available data."}
Secondary endpoints
- {"endpoint_text":"- Effect of CBD on Fear extinction (i.e. physiological responses and subjective fear)","definition_or_measurement_approach":"Physiological responses and subjective fear (as stated in the endpoint)"}
- {"endpoint_text":"- Effect of CBD on stress regulation with the Maastricht Acute Stress Test (MAST; i.e. Subjective stress, physiological responses, alpha-amylase and cortisol)","definition_or_measurement_approach":"Measured with the Maastricht Acute Stress Test (MAST): subjective stress, physiological responses, alpha-amylase and cortisol (as stated)"}
- {"endpoint_text":"- Effect of CBD on Sleep quality (i.e. questionnaires and a sleep watch)","definition_or_measurement_approach":"Measured by questionnaires and a sleep watch (as stated)"}
Recruitment
- Planned Sample Size
- 82
- Recruitment Window Months
- 18
- Consent Approach
- Participant informed consent is required (adult participants aged 18-65). A Subject Information Sheet and Informed Consent Form document is listed (L1_SIS and ICF), but specific details on who provides consent, age-specific documents, assent, or languages are not provided; exclusion criteria indicate inability to read or speak Dutch is exclusion, implying study materials are in Dutch.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 82
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-10-2024
- Latest Decision Or Authorization Date
- 29-10-2024
- Processing Time Days
- 7
- Number Of Sites
- 1
- Number Of Participants
- 82
Sites
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Brain
- Contact Person Name
- Antoin de Weijer
- Contact Person Email
- A.d.DeWeijer@umcutrecht.nl
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Utrecht
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Third parties
- {"country":"","full_name":"Brain Research and Innovation Center, Ministry of Defense","duties_or_roles":"Source of monetary support","organisation_type":""}
Investigational products
- Investigational Product Name
- Cannabidiol
- Active Substance
- CANNABIDIOL
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised (prodAuthStatus: 1)
- Maximum Dose
- 600 mg per day
- Investigational Product Name
- Softisan 378
- Modality
- Other
Related trials
Other published trials that may interest you.